Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
VERACYTE, INC. Chief Commercial Officer-CLIA John Leite reported an open-market sale of common stock under a pre-arranged Rule 10b5-1 trading plan. On March 4, 2026, he sold 5,260 shares at a weighted average price of $35.1868 per share, with individual sale prices ranging from $35.00 to $35.53. After this transaction, he continued to hold 107,580 shares of Veracyte common stock directly.
VERACYTE, INC. senior vice president and general counsel Annie McGuire reported selling 6,658 shares of common stock in open-market transactions on March 4, 2026. The sales were made under a Rule 10b5-1 trading plan adopted on August 29, 2025.
The reported weighted average sale prices were $35.2936 per share for 4,994 shares and $36.3393 per share for 1,664 shares. After these sales, McGuire directly owned 94,706 shares of Veracyte common stock.
VCYT files a notice of a proposed affiliate sale of 6,658 Restricted Stock Units. The filing lists the securities to be sold as Common — Restricted Stock Units with an effective date of 03/02/2026. The excerpt also shows a prior 10b5-1 sale of 10,739 common shares on 12/16/2025 attributed to Ann McGuire and identifies Morgan Stanley Smith Barney LLC as the broker.
Marc Stapley reported a sale of 15,000 common shares on 01/22/2026, with proceeds shown as $1,915,576.23. The filing also lists intended issuer-side units: 34,398 Performance Stock Units dated 02/26/202611,125 Restricted Stock Units dated 03/02/2026
The transactions are reported on a Form 144 and the sale was routed through Morgan Stanley Smith Barney LLC on the NASDAQ market.
Veracyte, Inc. senior vice president and general counsel Annie McGuire reported a tax-related share disposition tied to restricted stock units. On March 2, 2026, 6,902 shares of common stock at $36.01 per share were withheld to cover tax obligations in connection with RSU vesting and did not represent a sale. After this withholding, she directly owned 101,364 shares of Veracyte common stock.
VERACYTE, INC. executive Jonathan Wygant, the VP and Chief Accounting Officer, reported a tax-related share disposition. On March 2, 2026, 3,006 shares of common stock were withheld at $36.01 per share to cover tax obligations from vesting restricted stock units, and the footnote states this does not represent a sale. Following this withholding, he directly holds 34,909 shares of Veracyte common stock, including 495 shares purchased on January 31, 2026 through the company’s Employee Stock Purchase Plan.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported a Form 4 transaction involving company common stock. On March 2, 2026, 7,234 shares were withheld at a price of $36.01 per share to cover tax obligations tied to vesting restricted stock units and, as the disclosure notes, this does not represent a sale. After this tax-withholding disposition, Chambers directly owns 149,537 shares of Veracyte common stock.
Veracyte, Inc. Chief Commercial Officer-CLIA John Leite reported an automatic share disposition related to tax withholding. On March 2, 2026, 7,517 shares of common stock were withheld at a price of $36.01 per share to cover taxes on vesting restricted stock units, leaving him with 112,840 directly owned shares. The filing specifies this did not represent an open-market sale.